Top Markets
#1 Ontology Gas Ontology Gas +19.23%
#2 Status Status +13.13%
#3 Gas Gas +7.44%
#4 sBTC sBTC +5.95%
#5 Tornado Cash Tornado Cash +5.60%
#6 BCGame Coin BCGame Coin +5.45%
#7 Fake World Assets Fake World Assets +5.29%
#8 B3 (Base) B3 (Base) +5.22%
#9 aelf aelf +5.17%
#10 Derive Derive +4.65%
Coin of the day
Ontology Gas Ontology Gas
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
LianBio LianBio

LianBio

LIAN
Rang in Aktien #25845
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Aktienkurs
$0.42275
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$45.81M
Veränderung (1 Tag)
-0.89%
Veränderung (1 Jahr)
0.00%
Land
US
Handel LianBio (LIAN)

Kategorie

Healthcare
Kursverlauf für LianBio (LIAN)
Höchster Schlusskurs: $0.42 am 2025-07-01

Niedrigster Schlusskurs: $14.58 am 2021-11-01
Kursverlauf der Aktie von LianBio von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2025 44.04%
2024 -93.17%
2023 184.09%
2022 -82.11%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 35.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.21%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $119.69 -17.56%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 8.65%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 397.46%
US